Kang‐Yi Su
Impact in
-
- Lung Cancer Treatments and Mutations
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
Papers in
-
- Lung Cancer Treatments and Mutations 29
-
- DNA Repair Mechanisms 6
- RNA modifications and cancer 5
- Co-authors
- Sung‐Liang Yu (47 shared papers)Pan‐Chyr Yang (20 shared papers)Gee‐Chen Chang (21 shared papers)Jin‐Yuan Shih (9 shared papers)James Chih‐Hsin Yang (7 shared papers)Bing‐Ching Ho (9 shared papers)Jeremy J.W. Chen (17 shared papers)Hsuan‐Yu Chen (3 shared papers)
- Journals
- Scientific Reports (6 papers)PLoS ONE (5 papers)DNA repair (4 papers)Oncotarget (4 papers)Lung Cancer (4 papers)
- Partner nations
- TaiwanUnited StatesUnited Kingdom
In The Last Decade
Kang‐Yi Su
77 papers receiving 2.4k citations
Kang‐Yi Su's Hit Papers
Peers
Comparison fields: 5 of 122
- Pulmonary and Respiratory Medicine 1.1k
- Cancer Research 444
- Oncology 751
- Molecular Biology 754
- Parasitology 51
Countries citing papers authored by Kang‐Yi Su
This map shows the geographic impact of Kang‐Yi Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kang‐Yi Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kang‐Yi Su more than expected).
Fields of papers citing papers by Kang‐Yi Su
This network shows the impact of papers produced by Kang‐Yi Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kang‐Yi Su. The network helps show where Kang‐Yi Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Kang‐Yi Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 84 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2012 | 436 |
| 2 | 2010 | 148 | |
| 3 | 2011 | 133 | |
| 4 | 2017 | 117 | |
| 5 | 2018 | 81 | |
| 6 | 2007 | 78 | |
| 7 | 2014 | 73 | |
| 8 | 2019 | 66 | |
| 9 | 2005 | 64 | |
| 10 | 2000 | 62 | |
| 11 | 2016 | 57 | |
| 12 | 2014 | 55 | |
| 13 | 2014 | 49 | |
| 14 | 2018 | 47 | |
| 15 | 2018 | 46 | |
| 16 | 2011 | 44 | |
| 17 | 2018 | 44 | |
| 18 | 2015 | 41 | |
| 19 | 2018 | 35 | |
| 20 | 2020 | 35 |
About Kang‐Yi Su
Kang‐Yi Su is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Cancer Research and Epidemiology, having authored 84 papers that have together received 2.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (29 papers), Cancer Genomics and Diagnostics (8 papers), Lung Cancer Research Studies (7 papers), DNA Repair Mechanisms (6 papers), Colorectal Cancer Treatments and Studies (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), RNA modifications and cancer (5 papers) and Liver physiology and pathology (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.1k citations), Cancer Research (444 citations), Oncology (751 citations), Molecular Biology (754 citations) and Parasitology (51 citations). Kang‐Yi Su has collaborated with scholars based in Taiwan, United States and United Kingdom. Frequent co-authors include Sung‐Liang Yu, Pan‐Chyr Yang, Gee‐Chen Chang, Jin‐Yuan Shih, James Chih‐Hsin Yang, Bing‐Ching Ho, Jeremy J.W. Chen, Hsuan‐Yu Chen, Kun‐Chieh Chen and Jeng‐Sen Tseng. Their work appears in journals such as Scientific Reports, PLoS ONE, DNA repair, Oncotarget and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.